Full Breakdown
The Impact of HIV Treatment Cuts and Lenacapavir Rollout in Eswatini
3/24/2026, 9:40:00 PM
Overview of the HIV Crisis in Eswatini
Eswatini, once labeled the epicenter of the HIV epidemic, continues to grapple with high infection rates, particularly among vulnerable populations such as sex workers. Lianne, a 24-year-old who lost her parents to AIDS, exemplifies the struggles faced by many in the country. With limited access to HIV preventative medication, she turned to sex work to survive. The introduction of lenacapavir, a long-acting injectable HIV prevention drug, offers hope for individuals like Lianne, who are at high risk of infection.
The Rollout of Lenacapavir
Lenacapavir, developed by Gilead Sciences, is being rolled out in nine high-risk countries, including Eswatini. This drug, administered biannually, has been described as a potential game-changer in the fight against HIV. The United Nations aims to deliver lenacapavir to two million people by 2028, a critical initiative given the backdrop of significant cuts to foreign aid that previously supported HIV programs in Eswatini. The Global Fund to Fight AIDS, Tuberculosis, and Malaria is funding this initiative, which is crucial for reducing new infections.
Consequences of Foreign Aid Cuts
The recent cuts to foreign aid, particularly from the United States and the United Kingdom, have severely disrupted HIV response efforts in Eswatini. These reductions have led to the closure of mobile clinics that provided essential services, leaving many individuals without access to life-saving medications. David Maseko from HealthPlus for men highlights the dire situation, noting that the aid cuts have resulted in a significant number of people, especially from at-risk communities, being off their HIV medication.
Criticism of the Current Rollout Strategy
Despite the promise of lenacapavir, experts express concerns about the limited scope of its rollout. Dianne Stewart from the Global Fund emphasizes that reaching only two million people over three years falls far short of the global need, which UNAIDS estimates requires 20 million people on PrEP to effectively tackle the pandemic. Critics argue that without a comprehensive global strategy, the impact of lenacapavir will be limited, echoing past failures in addressing infectious diseases.
The Broader Implications of Treatment Cuts in the U.S.
In the United States, similar trends are emerging as at least 18 states have reduced access to AIDS Drug Assistance Programs (ADAP), which are vital for many living with HIV. Advocates warn that these cuts disproportionately affect Black Americans, who represent over 40% of new HIV diagnoses. The rising costs of medications, coupled with stagnant federal funding, threaten to undermine progress made in HIV treatment and prevention.
Official Statements & Responses
Advocates like David J. Johns from the National Black Justice Collective stress the urgency of addressing these funding cuts, stating, “These changes are essentially making it harder for people to qualify for assistance to afford drugs that have increased significantly in cost.” The cuts contradict national ambitions to end the HIV epidemic, as previously articulated by President Trump in 2019.
Verbatim Quotes
- “This has been a defining moment for the Aids epidemic,” — Dianne Stewart, Global Fund
- “We beg that they do not get tired of helping us,” — Lianne, HIV-positive individual
- “Two million people over three years is less than 10 per cent of that target.” — Dr. Diojki Bahati, Médecins Sans Frontières
- “This is life and death,” — David J. Johns, National Black Justice Collective
What's Next
As the rollout of lenacapavir continues, the focus remains on ensuring adequate funding and support for HIV programs globally. Advocacy groups are calling for increased federal funding for ADAP and other essential services to prevent further disruptions in treatment access. The future of HIV prevention and treatment hinges on a coordinated global response that addresses both local and international needs.
